ClinicalTrials.gg
CompletedNCT06109311ACHIEVE-5Updated Oct 1, 2026Results posted

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

A Phase 3 interventional study of Orforglipron and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 70 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Oct 1, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
8th of 15
546 · median 546
Started
2023
with 5 others
Phase 3
11 of 15
2 open now
Registered
9th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2D)
  • Have ≥7.0% [53 mmol/mol] to ≤10.5% [91 mmol/mol]
  • Have been treated with stable doses of the same formulation of the following for ≥90 days prior to screening visit 1 and have maintained the same doses through randomization:

    • insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD (units per kilogram per day) or ≥20 U/QD alone, or
    • insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD or ≥20 U/QD in combination with
    • metformin, or
    • SGLT-2 inhibitor, or
    • both metformin and SGLT-2 inhibitor.
  • Are of stable body weight (±5%) for at least 90 days prior to screening visit 1 and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
  • Have a (BMI) ≥23.0 kg/m\^2 at baseline.

Exclusion criteria

Exclusion Criteria:

  • Have functional classification III-IV congestive heart failure.
  • Have had any of the following cardiovascular conditions within 60 days prior to baseline.

    • acute myocardial infarction
    • cerebrovascular accident (stroke), or
    • hospitalization for congestive heart failure.
  • Have acute or chronic hepatitis, including a history of hepatitis, signs or symptoms of any other liver disease other than nonalcoholic fatty liver disease
  • Have had chronic or acute pancreatitis any time.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
546 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received matching placebo administered orally once daily (QD) and insulin glargine therapy (100 Units per milliliter (U/mL)) administered subcutaneously (SC) QD, over a period of 40 weeks.

    Drug: Placebo

  • Experimental
    3 mg Orforglipron QD

    Participants received oral orforglipron, initiated at 1 milligram (mg) and increased every 4 weeks until reaching to a maintenance dose of 3 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron QD

    Participants received oral orforglipron, initiated at 1 mg and increasing every 4 weeks until reaching to a maintenance dose of 12 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron QD

    Participants received oral orforglipron, initiated at 1 mg and increasing every 4 weeks until reaching to a maintenance dose of 36 mg QD and insulin glargine therapy 100 U/mL administered SC QD, over a period of 40 weeks.

    Drug: Orforglipron

Interventions

  • Administered orally.

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

    Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

    Time frame: Week 40

  2. Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)

    Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

    Time frame: Week 40

  3. Change From Baseline in Fasting Serum Glucose (FSG)

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  4. Percent Change From Baseline in Body Weight

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  5. Change From Baseline in Body Weight (kg)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  6. Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  7. Percent Change From Baseline in Triglycerides

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  8. Change From Baseline in Systolic Blood Pressure (mmHg)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  9. Change From Baseline in Daily Insulin Glargine Dose (IU/Day)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  10. Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

    Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

    Time frame: Week 40

  11. Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction

    Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

    Time frame: Week 40

  12. Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction

    Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

    Time frame: Week 40

  13. Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

    The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 40

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Started141137132136
All randomised participants141137132136
All randomised participants who received at least 1 dose of the study intervention140137132135
Completed131131124121
Not completed106815
Withdrew: Withdrawal by subject3226
Withdrew: Adverse event2214
Withdrew: Lost to follow-up0023
Withdrew: Physician decision1030
Withdrew: Protocol violation3001
Withdrew: Death0001
Withdrew: Non-compliance with study drug0100
Withdrew: Other1100

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
percentage of HbA1cPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Hemoglobin A1c (HbA1c)-0.77 ± 0.078-1.54 ± 0.097-2.05 ± 0.098-1.90 ± 0.111
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Least square (ls) mean difference (net): -0.77 · 95% CI -1.01 to -0.52
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · [ls mean difference (net): -1.28 · 95% CI -1.52 to -1.03
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Least square (ls) mean difference (net): -1.13 · 95% CI -1.39 to -0.86
SecondaryPercentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

Time frame:
Week 40
Reported as:
Number · Percentage of participants
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)
Percentage of participantsPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)23.6960.7480.7669.16
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 37.04 · 95% CI 26.67 to 47.42
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 57.07 · 95% CI 47.48 to 66.66
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 45.47 · 95% CI 35.34 to 55.60
SecondaryPercentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)

Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)
percentage of participantsPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)11.0945.9469.1260.07
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 34.85 · 95% CI 25.66 to 44.04
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 58.03 · 95% CI 48.69 to 67.36
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 48.98 · 95% CI 39.51 to 58.44
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligrams per deciliter (mg/dL)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Fasting Serum Glucose (FSG)-35.3 ± 2.36-40.5 ± 2.84-48.0 ± 2.74-44.5 ± 2.69
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = 0.161 · Ls mean difference (net): -5.2 · 95% CI -12.4 to 2.1
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -12.6 · 95% CI -19.7 to -5.5
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = 0.010 · Ls mean difference (net): -9.2 · 95% CI -16.2 to -2.2
SecondaryPercent Change From Baseline in Body Weight

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent changePlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Body Weight0.6 ± 0.44-2.7 ± 0.52-5.8 ± 0.58-6.1 ± 0.68
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -3.3 · 95% CI -4.6 to -2.0
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -6.4 · 95% CI -7.8 to -5.0
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -6.8 · 95% CI -8.4 to -5.2
SecondaryChange From Baseline in Body Weight (kg)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline in Body Weight (kg)
Kilogram (kg)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Body Weight (kg)0.5 ± 0.39-2.2 ± 0.48-5.0 ± 0.49-5.2 ± 0.64
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -2.6 · 95% CI -3.8 to -1.4
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -5.5 · 95% CI -6.7 to -4.3
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -5.6 · 95% CI -7.1 to -4.2
SecondaryPercent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol
Percent changePlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol-1.13 ± 2.679-3.90 ± 2.346-7.64 ± 2.597-7.81 ± 2.450
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = 0.437 · Ls mean difference (net): -2.80 · 95% CI -9.53 to 4.43
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = 0.081 · Ls mean difference (net): -6.58 · 95% CI -13.46 to 0.85
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = 0.066 · Ls mean difference (net): -6.76 · 95% CI -13.45 to 0.46
SecondaryPercent Change From Baseline in Triglycerides

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Triglycerides
Percent changePlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percent Change From Baseline in Triglycerides-4.73 ± 3.398-4.80 ± 3.149-17.45 ± 3.040-14.71 ± 3.144
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = 0.987 · Ls mean difference (net): -0.08 · 95% CI -9.18 to 9.93
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = 0.005 · Ls mean difference (net): -13.35 · 95% CI -21.61 to -4.22
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = 0.031 · Ls mean difference (net): -10.48 · 95% CI -19.06 to -0.98
SecondaryChange From Baseline in Systolic Blood Pressure (mmHg)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (mmHg)
millimeters of mercury (mmHg)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Systolic Blood Pressure (mmHg)0.0 ± 1.03-1.9 ± 0.94-3.2 ± 1.13-2.2 ± 1.26
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = 0.182 · Ls mean difference (net): -1.9 · 95% CI -4.6 to 0.9
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = 0.039 · Ls mean difference (net): -3.2 · 95% CI -6.2 to -0.2
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = 0.179 · Ls mean difference (net): -2.2 · 95% CI -5.4 to 1.0
SecondaryChange From Baseline in Daily Insulin Glargine Dose (IU/Day)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\]. Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · International Units per day (IU/day)
Change From Baseline in Daily Insulin Glargine Dose (IU/Day)
International Units per day (IU/day)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Change From Baseline in Daily Insulin Glargine Dose (IU/Day)21.4 ± 2.418.9 ± 1.5710.2 ± 1.898.4 ± 2.28
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -12.6 · 95% CI -18.2 to -6.9
  • Placebo vs 12 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -11.2 · 95% CI -17.2 to -5.2
  • Placebo vs 36 mg Orforglipron QD · Mixed Models Analysis · p = <0.001 · Ls mean difference (net): -13.0 · 95% CI -19.5 to -6.5
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
percentage of participantsPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction16.1035.4252.6150.56
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 19.32 · 95% CI 9.12 to 29.53
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 36.51 · 95% CI 25.97 to 47.05
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 34.46 · 95% CI 23.62 to 45.29
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction

Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction
percentage of participantsPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction4.2415.7023.3427.38
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Regression, Logistic · p = 0.001 · Risk difference (rd): 11.46 · 95% CI 4.42 to 18.50
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 19.09 · 95% CI 10.89 to 27.30
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = <0.001 · Risk difference (rd): 23.14 · 95% CI 14.33 to 31.96
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction

Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and SGLT-2 inhibitor use at randomization \[Yes or No\].

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction
percentage of participantsPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction2.526.189.9014.12
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · Regression, Logistic · p = 0.153 · Risk difference (rd): 3.66 · 95% CI -1.37 to 8.69
  • Placebo vs 12 mg Orforglipron QD · Regression, Logistic · p = 0.015 · Risk difference (rd): 7.38 · 95% CI 1.42 to 13.34
  • Placebo vs 36 mg Orforglipron QD · Regression, Logistic · p = 0.001 · Risk difference (rd): 11.60 · 95% CI 4.64 to 18.56
SecondaryChange From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · t-score
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores
t-scorePlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Physical Component Score0.71 ± 0.4910.47 ± 0.4961.07 ± 0.5920.35 ± 0.572
Mental Component Score0.13 ± 0.6731.11 ± 0.6930.19 ± 0.7000.98 ± 0.514
Statistical analysis
  • Placebo vs 3 mg Orforglipron QD · ANCOVA · p = 0.728 · Ls mean difference (net): -0.24 · 95% CI -1.57 to 1.10
  • Placebo vs 12 mg Orforglipron QD · ANCOVA · p = 0.622 · Ls mean difference (net): 0.37 · 95% CI -1.10 to 1.84
  • Placebo vs 36 mg Orforglipron QD · ANCOVA · p = 0.628 · Ls mean difference (net): -0.35 · 95% CI -1.78 to 1.07
  • Placebo vs 3 mg Orforglipron QD · ANCOVA · p = 0.280 · Ls mean difference (net): 0.98 · 95% CI -0.80 to 2.76
  • Placebo vs 12 mg Orforglipron QD · ANCOVA · p = 0.947 · Ls mean difference (net): 0.06 · 95% CI -1.77 to 1.89
  • Placebo vs 36 mg Orforglipron QD · ANCOVA · p = 0.303 · Ls mean difference (net): 0.85 · 95% CI -0.77 to 2.48

Adverse events

Collected over Baseline to end of safety follow-up (up to 42 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/140 (0%)6/140 (4.3%)111/140 (79.3%)
3 mg Orforglipron QD0/137 (0%)7/137 (5.1%)110/137 (80.3%)
12 mg Orforglipron QD0/132 (0%)9/132 (6.8%)105/132 (79.5%)
36 mg Orforglipron QD1/135 (0.7%)10/135 (7.4%)114/135 (84.4%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
Acute myocardial infarctionCardiac disorders1/1400/1372/1320/135
HypoglycaemiaMetabolism and nutrition disorders0/1400/1372/1321/135
Benign prostatic hyperplasiaReproductive system and breast disorders0/650/720/771/73
Angina unstableCardiac disorders0/1400/1371/1320/135
Coronary artery diseaseCardiac disorders0/1400/1371/1320/135
InfluenzaInfections and infestations0/1400/1371/1320/135
Urinary tract infectionInfections and infestations0/1400/1371/1320/135
Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders0/1400/1371/1320/135
Salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1400/1371/1320/135
HypoaesthesiaNervous system disorders0/1400/1371/1320/135
Most frequent other events
Showing 10 of 476
Most frequent other events
EventPlacebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QD
NauseaGastrointestinal disorders6/14029/13737/13241/135
Diabetic retinopathyEye disorders39/14024/13721/13232/135
VomitingGastrointestinal disorders0/14011/13720/13229/135
Decreased appetiteMetabolism and nutrition disorders6/14019/13721/13228/135
DiarrhoeaGastrointestinal disorders10/14026/13718/13222/135
ConstipationGastrointestinal disorders6/14020/13715/13210/135
Lipase increasedInvestigations4/1406/13712/13213/135
DyspepsiaGastrointestinal disorders4/1408/13712/1328/135
Blood creatine phosphokinase increasedInvestigations2/1406/1376/13212/135
InfluenzaInfections and infestations12/1402/1372/1327/135

Baseline characteristics

All randomised participants.

Age, Categorical
Age, Categorical(Participants)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
<=18 years00000
Between 18 and 65 years87948088349
>=65 years54435248197
Sex: Female, Male
Sex: Female, Male(Participants)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Female75655562257
Male66727774289
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Hispanic or Latino59535559226
Not Hispanic or Latino82837777319
Unknown or Not Reported01001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
American Indian or Alaska Native10102
Asian36353336140
Native Hawaiian or Other Pacific Islander00011
Black or African American1315121353
White82807780319
More than one race557623
Unknown or Not Reported42208
Region of Enrollment
Region of Enrollment(participants)Placebo3 mg Orforglipron QD12 mg Orforglipron QD36 mg Orforglipron QDTotal
Romania33323130126
United States26262627105
Japan1918181873
China1716141764
Brazil46454344178
08

Study locations

70 sites
  • MD First Research - Chandler
    Chandler, Arizona 85286, United States
  • Phoenix Clinical LLC
    Phoenix, Arizona 85014, United States
  • SanRo Clinical Research Group
    Bryant, Arkansas 72022, United States
  • Velocity Clinical Research, Gardena
    Gardena, California 90247, United States
  • Loma Linda University Health System
    Loma Linda, California 92350, United States
  • Western University of Health Sciences
    Pomona, California 91766, United States
  • Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.
    Toluca Lake, California 91602, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Care Access - Brandon
    Brandon, Florida 33510, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Orita Clinical Research
    Decatur, Georgia 30034, United States
  • Bingham Memorial Hospital
    Blackfoot, Idaho 83221, United States
  • St. Luke's Humphreys Diabetes Center: Boise
    Boise, Idaho 83702, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington
    Lexington, Kentucky 40503, United States
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
  • Velocity Clinical Research, Mt. Auburn
    Cincinnati, Ohio 45219, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Tristar Clinical Investigations
    Philadelphia, Pennsylvania 19114, United States
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
  • Lifedoc Research - Lenox Park Drive
    Memphis, Tennessee 38115, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
  • CEDOES
    Vitória, Espírito Santo 29055450, Brazil
  • L2IP - Instituto de Pesquisas Clínicas
    Brasília, Federal District 70200730, Brazil
  • Quanta Diagnóstico e Terapia
    Curitiba, Paraná 80040-110, Brazil
  • Insight Centro de Pesquisas
    Porto Alegre, Rio Grande do Sul 90560-003, Brazil
  • Centro de Pesquisa Sao Lucas
    Campinas, São Paulo 13060-803, Brazil
  • Centro Multidisciplinar de Estudos Clinicos
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas
    São José dos Campos, São Paulo 12243-280, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 20241-180, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230011, China
  • Wannan Medical College Yijishan Hospital
    Wuhu, Anhui 241001, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100051, China
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality 401147, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210012, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Tokuyama Clinic
    Mihama-ku,Chiba City, Chiba 261-0004, Japan
  • Hasegawa Medical Clinic
    Chitose, Hokkaido 066-0032, Japan
  • MinamiAkatsukaClinic
    Mito, Ibaraki 311-4153, Japan
  • Matoba Internal Medicine Clinic
    Ebina, Kanagawa 243-0432, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Shiraiwa Medical Clinic
    Kashihara, Osaka 582-0005, Japan
  • The Institute of Medical Science, Asahi Life Foundation
    Chuo-ku, Tokyo 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Medical Corporation Sato Medical clinic
    Ootaku, Tokyo 143-0015, Japan
  • Tama Center Clinic Mirai
    Tama, Tokyo 206-0633, Japan
  • Jinnouchi Hospital
    Kumamoto, 862-0976, Japan
  • Kansai Electric Power Hospital
    Osaka, 553-0003, Japan
  • Abe Clinic
    Ōita, 870-0039, Japan
  • Centro de Endocrinologia y Nutricion
    Caguas, 00725, Puerto Rico
  • FDI Clinical Research
    San Juan, 00927, Puerto Rico
  • Diabdana
    Oradea, Bihor County 410147, Romania
  • C.M.D.T.A. Neomed
    Brasov, Brașov County 500283, Romania
  • Geea Medical Easy Diet
    Bucharest, Bucharest 010627, Romania
  • Centrul Medical NutriLife
    Bucharest, Bucharest 013764, Romania
  • Centrul Medical Endocrinologie si Diabet Dr. Paveliu
    Bucharest, Bucharest 50538, Romania
  • CMI DNBM Dr. Pop Lavinia
    Baia Mare, Maramureş 430222, Romania
  • SC Dentosim Queen SRL - Centrul Medical Diamed
    Târgu Mureş, Mureș County 540098, Romania
  • Milena Sante
    Galați, 800001, Romania
  • Diamed Obesity
    Galați, 800291, Romania
  • Clinica Korall
    Satu Mare, 440055, Romania
09

References and documents

Publications

  • Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernandez Lando L, Tobian J. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026 Aug 4;336(5):389-399. doi: 10.1001/jama.2026.9512. PubMed 42251769 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Sep 2025, 22 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Oct 31, 2023
StartActual
Nov 10, 2023
Primary completionActual
Sep 15, 2025
CompletionActual
Sep 15, 2025
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Interventions
Arms added: 3 mg Orforglipron QD·12 mg Orforglipron QD·36 mg Orforglipron QD; arms removed: Orforglipron Dose 1·Orforglipron Dose 2·Orforglipron Dose 3
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOrforglipron Dose 1, 2: Change fromFrom Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 40
Oct 1, 2026
Documents
Secondary outcomes
10 edited, 3 added, 4 removed
What changed in the outcomes
  • EditedOrforglipron Dose 3:Percent Change fromFrom Baseline in HbA1cBody WeightTime frame: Baseline, Week 40
  • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of < 7.0% (53 millimoles per mole (mmol/molMol))Time frame: Baseline to Week 40 → Week 40
  • EditedPercentage of Participants Who AchievedWith an HbA1c ≤Target Value of < 6.5% (48 mmol/molMol)Time frame: Baseline to Week 40 → Week 40
  • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 40
  • EditedPercentage Change fromFrom Baseline in Body Weight (kg)Time frame: Baseline, Week 40
  • EditedPercent Change fromFrom Baseline in Body WeightTriglyceridesTime frame: Baseline, Week 40
  • EditedPercentagePercent Change fromFrom Baseline in nonNon-HDL (nonNon-high-density lipoproteinLipoprotein) CholesterolTime frame: Baseline, Week 40
  • EditedPercentage Change fromFrom Baseline in TriglyceridesSystolic Blood Pressure (mmHg)Time frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Daily Insulin Glargine Dose (IU/Day)Time frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Short Form 36--36 Health Survey Version 2 (SF-36v2) Acute Form Domain(Physical-Component and SummaryMental-Component) ScoresTime frame: Baseline, Week 40
  • AddedPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight ReductionTime frame: Week 40
  • AddedPercentage of Participants With Greater Than or Equal to (≥) 10% Body Weight ReductionTime frame: Week 40
  • AddedPercentage of Participants With Greater Than or Equal to (≥) 15% Body Weight ReductionTime frame: Week 40
  • RemovedChange from Baseline in Systolic Blood PressureTime frame: Baseline, Week 40
  • RemovedPercentage of Participants Who Achieved Weight Loss of ≥5%Time frame: Baseline to Week 40
  • RemovedPercentage of Participants Who Achieved Weight Loss of ≥10%Time frame: Baseline to Week 40
  • RemovedPercentage of Participants Who Achieved Weight Loss of ≥15% from BaselineTime frame: Baseline to Week 40
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOrforglipron Dose 1, 2: Change fromFrom Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline, Week 40
    Secondary outcomes 10 edited, 3 added, 4 removed
    What changed in the outcomes
    • EditedOrforglipron Dose 3:Percent Change fromFrom Baseline in HbA1cBody WeightTime frame: Baseline, Week 40
    • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of < 7.0% (53 millimoles per mole (mmol/molMol))Time frame: Baseline to Week 40 → Week 40
    • EditedPercentage of Participants Who AchievedWith an HbA1c ≤Target Value of < 6.5% (48 mmol/molMol)Time frame: Baseline to Week 40 → Week 40
    • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 40
    • EditedPercentage Change fromFrom Baseline in Body Weight (kg)Time frame: Baseline, Week 40
    • EditedPercent Change fromFrom Baseline in Body WeightTriglyceridesTime frame: Baseline, Week 40
    • EditedPercentagePercent Change fromFrom Baseline in nonNon-HDL (nonNon-high-density lipoproteinLipoprotein) CholesterolTime frame: Baseline, Week 40
    • EditedPercentage Change fromFrom Baseline in TriglyceridesSystolic Blood Pressure (mmHg)Time frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Daily Insulin Glargine Dose (IU/Day)Time frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Short Form 36--36 Health Survey Version 2 (SF-36v2) Acute Form Domain(Physical-Component and SummaryMental-Component) ScoresTime frame: Baseline, Week 40
    • AddedPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight ReductionTime frame: Week 40
    • AddedPercentage of Participants With Greater Than or Equal to (≥) 10% Body Weight ReductionTime frame: Week 40
    • AddedPercentage of Participants With Greater Than or Equal to (≥) 15% Body Weight ReductionTime frame: Week 40
    • RemovedChange from Baseline in Systolic Blood PressureTime frame: Baseline, Week 40
    • RemovedPercentage of Participants Who Achieved Weight Loss of ≥5%Time frame: Baseline to Week 40
    • RemovedPercentage of Participants Who Achieved Weight Loss of ≥10%Time frame: Baseline to Week 40
    • RemovedPercentage of Participants Who Achieved Weight Loss of ≥15% from BaselineTime frame: Baseline to Week 40
    Interventions Arms added: 3 mg Orforglipron QD·12 mg Orforglipron QD·36 mg Orforglipron QD; arms removed: Orforglipron Dose 1·Orforglipron Dose 2·Orforglipron Dose 3
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06109311
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Nov 10, 2023
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion